Quantifying Remyelination Using χ-Separation in White Matter and Cortical Multiple Sclerosis Lesions
- PMID: 39213476
- PMCID: PMC11362958
- DOI: 10.1212/WNL.0000000000209604
Quantifying Remyelination Using χ-Separation in White Matter and Cortical Multiple Sclerosis Lesions
Abstract
Background and objectives: Myelin and iron play essential roles in remyelination processes of multiple sclerosis (MS) lesions. χ-separation, a novel biophysical model applied to multiecho T2*-data and T2-data, estimates the contribution of myelin and iron to the obtained susceptibility signal. We used this method to investigate myelin and iron levels in lesion and nonlesion brain areas in patients with MS and healthy individuals.
Methods: This prospective MS cohort study included patients with MS fulfilling the McDonald Criteria 2017 and healthy individuals, aged 18 years or older, with no other neurologic comorbidities. Participants underwent MRI at baseline and after 2 years, including multiecho GRE-(T2*) and FAST-(T2) sequences. Using χ-separation, we generated myelin-sensitive and iron-sensitive susceptibility maps. White matter lesions (WMLs), cortical lesions (CLs), surrounding normal-appearing white matter (NAWM), and normal-appearing gray matter were segmented on fluid-attenuated inversion recovery and magnetization-prepared 2 rapid gradient echo images, respectively. Cross-sectional group comparisons used Wilcoxon rank-sum tests, longitudinal analyses applied Wilcoxon signed-rank tests. Associations with clinical outcomes (disease phenotype, age, sex, disease duration, disability measured by Expanded Disability Status Scale [EDSS], neurofilament light chain levels, and T2-lesion number and volume) were assessed using linear regression models.
Results: Of 168 patients with MS (median [interquartile range (IQR)] age 47.0 [21.7] years; 101 women; 6,898 WMLs, 775 CLs) and 103 healthy individuals (age 33.0 [10.5] years, 57 women), 108 and 62 were followed for a median of 2 years, respectively (IQR 0.1; 5,030 WMLs, 485 CLs). At baseline, WMLs had lower myelin (median 0.025 [IQR 0.015] parts per million [ppm]) and iron (0.017 [0.015] ppm) than the corresponding NAWM (myelin 0.030 [0.012]; iron 0.019 [0.011] ppm; both p < 0.001). After 2 years, both myelin (0.027 [0.014] ppm) and iron had increased (0.018 [0.015] ppm; both p < 0.001). Younger age (p < 0.001, b = -5.111 × 10-5), lower disability (p = 0.04, b = -2.352 × 10-5), and relapsing-remitting phenotype (RRMS, 0.003 [0.01] vs primary progressive 0.002 [IQR 0.01], p < 0.001; vs secondary progressive 0.0004 [IQR 0.01], p < 0.001) at baseline were associated with remyelination. Increment of myelin correlated with clinical improvement measured by EDSS (p = 0.015, b = -6.686 × 10-4).
Discussion: χ-separation, a novel mathematical model applied to multiecho T2*-images and T2-images shows that young RRMS patients with low disability exhibit higher remyelination capacity, which correlated with clinical disability over a 2-year follow-up.
Conflict of interest statement
J. Müller has nothing to disclose about this work, he has received financial support by the Swiss National Science Foundation (grant no. P500PM_214230). P.-J. Lu reports no disclosures relevant to the manuscript. A. Cagol was supported by EUROSTAR E!113682 HORIZON2020 and received speaker honoraria from Novartis. E. Ruberte reports no disclosures relevant to the manuscript. H.-G. Shin reports no disclosures relevant to the manuscript. M. Ocampo-Pineda reports no disclosures relevant to the manuscript. X. Chen reports no disclosures relevant to the manuscript. C. Tsagkas has nothing to disclose about this work, he has received financial support by the Swiss National Science Foundation (grant no. 320030_156860 and P500PM_206620), the National Multiple Sclerosis Society (grant no. FG-2107-38022), the Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung (application ID 02/2015), and the University of Basel (grant no. 3MS1020 and 3MS1049). M. Barakovic is an employee of Hays plc and a consultant for F. Hoffmann-La Roche Ltd. R. Galbusera reports no disclosures relevant to the manuscript. M. Weigel has received research funding by Biogen for developing spinal cord MRI. S.A. Schaedelin reports no disclosures relevant to the manuscript. Y. Wang received a grant from NIH and reports patents for QSM owned by Cornell University, owns stock/stock options in Medimagemetric. T.D. Nguyen reports no disclosures relevant to the manuscript. P. Spincemaille is an inventor of QSM-related patents issued to Cornell University and holds equity in Medimagemetric LLC, he is a paid consultant for Medimagemetric LLC. L. Kappos has received no personal compensation. His institutions (University Hospital Basel/Foundation Clinical Neuroimmunology and Neuroscience Basel) have received and used exclusively for research support: payments for steering committee and advisory board participation, consultancy services, and participation in educational activities from Actelion, Bayer, BMS, df-mp Molnia & Pohlmann, Celgene, Eli Lilly, EMD Serono, Genentech, Glaxo Smith Kline, Janssen, Japan Tobacco, Merck, MH Consulting, Minoryx, Novartis, F. Hoffmann-La Roche Ltd., Senda Biosciences Inc., Sanofi, Santhera, Shionogi BV, TG Therapeutics, and Wellmera, and license fees for Neurostatus-UHB products, grants from Novartis, Innosuisse, and Roche. J. Kuhle received speaker fees, research support, travel support, and/or served on advisory boards by Swiss MS Society, Swiss National Research Foundation (320030_189140/1), University of Basel, Progressive MS Alliance, Bayer, Biogen, Bristol Myers Squibb, Celgene, Merck, Novartis, Octave Bioscience, Roche, and Sanofi. J. Lee is an inventor of a χ-separation-related patent owned by Seoul National University and received financial support from National Research Foundation of Korea (NRF-2021R 1A2B5B03002783). C. Granziera, the University Hospital Basel (USB), as the employer of Cristina Granziera, has received the following fees which were used exclusively for research support (1) advisory board and consultancy fees from Actelion, Genzyme-Sanofi, Novartis, GeNeuro, and Roche; (2) speaker fees from Genzyme-Sanofi, Novartis, GeNeuro and Roche; and (3) research support from Siemens, GeNeuro, and Roche, she is supported by the Swiss National Science Foundation (SNSF) grant PP00P3_176984, the Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung and the EUROSTAR E!113682 HORIZON2020. Go to
Figures






References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources